CERETEC Drug Patent Profile
When do Ceretec patents expire, and when can generic versions of Ceretec launch?
Ceretec is a drug marketed by Ge Healthcare and is included in one NDA.
The generic ingredient in CERETEC is technetium tc-99m exametazime kit. There is one drug master file entry for this compound. Three suppliers are listed for this compound. Additional details are available on the technetium tc-99m exametazime kit profile page.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for CERETEC?
- What are the global sales for CERETEC?
- What is Average Wholesale Price for CERETEC?
Summary for CERETEC
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 2 |
| Raw Ingredient (Bulk) Api Vendors: | 4 |
| Clinical Trials: | 2 |
| Drug Prices: | Drug price information for CERETEC |
| What excipients (inactive ingredients) are in CERETEC? | CERETEC excipients list |
| DailyMed Link: | CERETEC at DailyMed |
Recent Clinical Trials for CERETEC
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Norton Healthcare | Phase 2 |
| University of Kentucky | Phase 2 |
| Thomas Hatschek | Phase 2 |
Pharmacology for CERETEC
| Drug Class | Radioactive Diagnostic Agent |
| Mechanism of Action | Radiopharmaceutical Activity |
US Patents and Regulatory Information for CERETEC
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ge Healthcare | CERETEC | technetium tc-99m exametazime kit | INJECTABLE;INJECTION | 019829-001 | Dec 30, 1988 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for CERETEC
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Ge Healthcare | CERETEC | technetium tc-99m exametazime kit | INJECTABLE;INJECTION | 019829-001 | Dec 30, 1988 | ⤷ Start Trial | ⤷ Start Trial |
| Ge Healthcare | CERETEC | technetium tc-99m exametazime kit | INJECTABLE;INJECTION | 019829-001 | Dec 30, 1988 | ⤷ Start Trial | ⤷ Start Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for CERETEC
See the table below for patents covering CERETEC around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Australia | 2711884 | ⤷ Start Trial | |
| Australia | 564636 | ⤷ Start Trial | |
| Canada | 1231715 | COMPLEXES DE TECHNETIUM-99M AVEC DES OXIMES D'ALCOYLENE-AMINE (COMPLEXES OF TECHNETIUM-99M WITH ALKYLENE AMINE OXIMES) | ⤷ Start Trial |
| Czechoslovakia | 271306 | METHOD OF 99M TECHNETIUM'S LIPOPHILE MACROCYCLIC COMPLEXES PRODUCTION | ⤷ Start Trial |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for CERETEC
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1178838 | 300736 | Netherlands | ⤷ Start Trial | PRODUCT NAME: TILMANOCEPT, DESGEWENST GELABELD MET TECHNETIUM TC 99M; REGISTRATION NO/DATE: EU/1/14/955 20141119 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2026 - 2027
NCE-1 Patent Challenge Dates 2026 - 2027
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2026, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch